查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863267

CT/NG檢測市場按技術、產品類型、最終用戶和檢測類型分類－2025-2032年全球預測

CT/NG Testing Market by Technology, Product Type, End User, Test Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，CT/NG 檢測市場將成長至 31.6 億美元，複合年成長率為 7.70%。

關鍵市場統計數據
基準年 2024 17.4億美元
預計年份：2025年 18.7億美元
預測年份 2032 31.6億美元
複合年成長率 (%) 7.70%

為披衣菌感染和淋病檢測診斷技術的發展指明清晰的策略方向，為經營團隊技術結構、臨床效用和採購影響。

本執行摘要對當前披衣菌感染和淋病檢測的臨床診斷趨勢進行了全面的分析回顧，重點關注正在重塑臨床實踐的技術趨勢、相關人員的行為以及營運壓力。本文將診斷創新置於更廣泛的醫療服務背景下進行探討，指出診斷準確性、結果出具時間以及與治療路徑的整合日益影響著臨床效用和採購決策。因此，本報告旨在使高階主管了解影響診斷應用的關鍵轉折點，並重點闡述臨床營運和商業策略的實際考量。

重點，引言部分從多個觀點審視了診斷領域：包括培養、雜合反應、免疫檢測和核酸增幅檢查技術能力；耗材、儀器和軟體等產品和服務；以及學術研究機構、診所、診斷實驗室和醫院等終端使用者的需求。在建構了這個結構化觀點之後，後續章節將技術細節轉化為對臨床實務、供應鏈和法規遵循的策略意義。因此，讀者將能夠清楚地了解診斷方法與實際應用場景之間的聯繫，從而能夠更明智地確定投資和夥伴關係機會的優先順序。

分子診斷加速、多重檢測和分散式診斷將如何全面重塑衣原體/淋球菌檢測的臨床工作流程和籌資策略

分子診斷技術的加速應用、多重檢測需求的不斷成長以及對分散式檢查模式的重視（即在更靠近診療點的位置進行高靈敏度檢測），正在推動診斷領域的變革性變化。核酸增幅檢查已從集中式實驗室轉向快速工作流程，這得益於等溫擴增技術的進步和聚合酵素鏈鎖反應平台穩定性的提升。這促使臨床路徑優先考慮那些既能加快出結果速度又能確保診斷準確性的檢測方法，從而促使醫院和診所重新思考其實驗室流程和分診通訊協定。

同時，軟體和資料管理工具的融合正在改變檢測結果的解讀和應用方式。自動化分析儀和互聯設備提高了檢測通量，並減少了人為錯誤。這項技術變革與不斷變化的監管要求和品管框架相互作用，迫使製造商和實驗室管理人員加強對檢驗、可追溯性和互通性的投入。此外，耗材創新、檢測設計和儀器功能正在推動更實用的雙重檢測策略，從而能夠在單一工作流程中同時檢測披衣菌感染衣原體和淋病奈瑟菌。這些趨勢正在推動臨床、商業和營運職能部門進行策略性重新評估，需要研發、生產和客戶支援團隊之間的協調應對。

評估2025年美國關稅對診斷產品供應鏈、採購慣例以及製造商在地化決策的影響，並分析其對營運的影響。

美國2025年實施的關稅調整的累積影響正對診斷供應鏈、採購決策和製造商成本結構產生重大影響。進口試劑、設備和某些零件的關稅調整增加了到岸成本，促使買賣雙方重新評估籌資策略並探索替代物流模式。為此，許多相關人員正在加快近岸外包的討論，實現供應商組合多元化，並重新評估庫存緩衝，以維持檢測服務的連續性並應對價格的暫時波動。

這些貿易政策的變化也影響產品藍圖和投資時間表。先前依賴低成本國際供應鏈的製造商被迫考慮本地生產，並與經銷商協商新的商業條款。因此，採購部門優先考慮提高合約透明度，並簽署長期供應協議，以確保關鍵耗材和PCR設備的穩定供應。從臨床角度來看，關稅凸顯了彈性供應計畫的重要性。診斷實驗室和醫院網路正致力於尋找檢驗的替代檢測方法和冗餘設備平台，以降低試劑供應限制和進口成本波動帶來的營運風險。

綜合細分分析揭示了技術差異、產品組合、最終用戶需求和測試類型如何融合，從而驅動診斷選擇和實施策略。

關鍵的細分洞察揭示了技術選擇、產品形式、最終用戶需求和檢測類型如何相互交織，從而影響技術採納路徑和採購優先順序。技術細分涵蓋培養方法、雜合反應檢測、免疫檢測和核酸增幅檢查。在核酸增幅檢查中，相關人員區分等溫擴增和聚合酵素鏈鎖反應。等溫擴增方法包括恒溫環型核酸擴增(LAMP) 和轉錄媒介增幅(TMA)，而聚合酵素鏈鎖反應則包括嵌套 PCR 和即時PCR等變體，每種方法在性能、通量和工作流程方面各有優劣。這些技術差異決定了臨床適應症標準和實驗室整合要求，在選擇診斷解決方案時，應在評估通訊協定的製定中加以體現。

產品類型細分包括耗材和試劑、儀器以及軟體和服務。耗材和試劑包括品管樣品、套件以及探針和引子。儀器涵蓋從自動化系統到雜合反應分析儀和PCR儀等各種類型。軟體和服務則著重於資料管理、連結性和生命週期支援。最終用戶細分包括學術研究機構、診所、診斷實驗室和醫院。每個機構都有其獨特的通量需求、認證限制和採購週期，這些都會影響產品選擇。檢測類型細分重點在於披衣菌感染檢測、雙重檢測和淋病檢測。雙重檢測尤其因其操作效率高且在尋求整合診斷路徑的環境中具有臨床價值而日益普及。這些細分觀點有助於根據目標使用者和應用程式場景系統地確定投資、檢驗和商業化工作的優先順序。

不同地區在診斷方法應用、監管複雜性和採購行為方面的差異（美洲、歐洲、中東和非洲、亞太地區）需要針對每個地區制定量身定做的商業性策略。

美洲、歐洲、中東和非洲地區以及亞太地區的法規環境、臨床應用和供應鏈結構各不相同，導致製造商和採購商的優先事項也存在差異。在美洲，對快速、靈敏的分子診斷的需求以及完善的檢測網路推動了核酸擴增方法和自動化系統的廣泛應用，但採購團隊仍然專注於成本和供應連續性問題。同時，在歐洲、中東和非洲地區，不同的管理體制和醫療基礎設施造成了不同的市場准入考量，因此需要製定適應性強的市場進入策略和靈活的檢驗方案，以適應不同的認證途徑。

亞太地區的特點是部分都市區創新技術的快速普及以及各市場臨床基礎設施的顯著差異，這凸顯了模組化儀器平台和可客製化試劑組的價值。在所有地區，隨著醫療系統優先考慮簡化患者就診流程和減少追蹤次數，雙重檢測和就地檢驗方案的重要性日益凸顯。此外，區域採購政策、公共衛生篩檢計畫和報銷環境持續影響終端使用者的購買行為，這凸顯了客製化商業模式、在地化夥伴關係以及監管合規準備對於在不同地區取得成功的重要性。

競爭分析重點在於檢測創新、儀器自動化、數位化連接和供應鏈韌性，這些因素決定了診斷公司的成功。

診斷生態系統中的主要企業正在積極尋求差異化策略，涵蓋檢測創新、設備自動化和數位化連接等領域，同時應對監管審查和供應鏈限制。成功的企業將強大的研發開發平臺（專注於高靈敏度核酸擴增和多重檢測技術開發）與可擴展的耗材和試劑生產能力相結合。同時，對自動化平台、雜合反應分析儀和PCR儀的投資，能夠簡化工作流程並減少人工操作時間，仍是客戶提升營運效率的關鍵差異化因素。

為了加快產品上市速度並拓展分銷網路，策略聯盟和OEM協議正變得越來越普遍。那些透過軟體和服務增強產品線，從而實現結果管理、分析和合規支援的公司，往往能夠更深入地融入醫療保健系統。此外，那些擁有靈活的供應模式和透明的品質系統的公司，更有能力贏得大型機構客戶的信任，並在採購競標中脫穎而出。總而言之，創新、規模、互聯互通和供應韌性這四項能力，是當今CT/NG診斷市場競爭優勢的核心要素。

給領導者的具體策略建議：整合研發、製造彈性、互通性和客製化的商業模式，以加速推廣應用並降低中斷風險。

產業領導者應優先考慮整合技術投資、供應鏈韌性和以客戶為中心的支援的策略，以掌握臨床和商業性機會。首先，推動研發，開發穩健的核酸增幅檢查以及多重和雙聯檢測技術，將滿足臨床對快速、準確和一體化診斷​​的需求，同時提升臨床工作流程的效率。其次，透過近岸外包、契約製造夥伴關係或多元化的供應商網路來增強生產彈性，將降低貿易政策變化帶來的風險，並減少單一來源供應中斷的影響。

此外，企業應提高儀器和軟體的互通性，以降低使用不同分析儀器的實驗室和診所的採用障礙。對監管資訊和快速檢驗流程的策略性投資將有助於企業進入不同地區的市場。此外，針對學術研究機構、診所、診斷實驗室和醫院等各自獨特的採購週期，開發客製化的商業模式，將有助於提高合約中標率和客戶維繫。最後，促進與公共衛生計畫和臨床網路的舉措，可以增強信譽並加速產品推廣，尤其對於那些能夠在篩檢和治療流程中即時產生實際效益的雙重檢測解決方案而言更是如此。

嚴謹的多方法研究框架，結合了關鍵相關利益者訪談、技術檢測評估和二手證據，提供了檢驗且可操作的診斷見解。

我們的研究途徑採用了多方法框架，結合了關鍵相關人員對話、技術檢測審查和二手文獻綜合，以提供可靠的實用見解。主要研究包括對實驗室技術人員、臨床決策者、採購人員和監管專家進行結構化訪談，以了解操作限制、檢驗要求和實施促進因素。這些對話輔以對檢測設計、儀器規格和工作流程整合的技術審查，以比較不同應用場景下的性能特徵和適用性。

二次研究利用已發布的監管文件、臨床指南和同行評審文獻，對核酸擴增方法、雜合反應檢測和免疫檢測的臨床效用和證據標準進行了背景分析。資料綜合採用多資訊來源三角驗證法，以檢驗主題發現並識別一致的操作模式。品質保證措施包括對訪談結果進行交叉檢驗、系統記錄資料來源以及內部同行評審，以確保分析的嚴謹性。這種多層次的調查方法確保了結論和建議是基於真實的臨床實踐，同時兼顧了監管和供應鏈的實際情況。

本文綜合分析了診斷趨勢，闡述了技術融合、營運韌性和目標商業化如何協同作用，才能維持其應用並產生臨床影響。

總之，隨著分子技術、儀器自動化和數據整合技術的融合，衣原體/淋巴瘤診斷領域正經歷著積極的變革時期，這些技術共同推動了臨床路徑的改進和營運效率的提升。雙重檢測方法的興起和分散式檢查可行性的不斷提高，正在重塑施行地點；同時，關稅帶來的供應鏈壓力凸顯了生產靈活性和採購流程透明度的必要性。綜上所述，這些趨勢表明，未來要實現永續應用，技術能力必須與穩健的營運實務和有針對性的商業性合作相輔相成。

決策者面臨的挑戰顯而易見：產品開發和商業化計畫必須與最終用戶的實際限制、區域法規環境和供應鏈實際情況相符。這將使機構能夠加快臨床應用，加強客戶關係，並降低營運風險。未來發展需要協調投資於檢測創新、設備互通性和供應鏈網路設計，同時制定積極的監管計劃和客製化的市場推廣策略，以滿足學術機構、臨床實驗室、診所和醫院的多元化需求。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 照護現場分子診斷技術的出現縮短了CT/NG檢測的周轉時間
  • 整合數位健康平台，簡化CT/NG檢查預約與病患追蹤流程
  • 採用包含披衣菌感染/淋病雙球菌檢測和其他性行為感染傳染病檢測項目的多症候群檢測組合，以提高診斷準確性
  • 隨著遠端醫療的普及，對用於 CT/NG篩檢的家用自採集套件的需求日益成長。
  • 抗菌藥物抗藥性監測對淋球菌核酸擴增檢測技術開發及市場趨勢的影響
  • 監管過渡：下一代披衣菌感染/淋病篩檢測試獲得FDA核准
  • 利用CRISPR基因編輯技術提升披衣菌感染和淋病檢測流程靈敏度的新方法

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第 8 章：按技術分類的 CT/NG 檢測市場

  • 培養方法
  • 雜合反應方法
  • 免疫檢測
  • 核酸增幅檢查
    • 等溫擴增
      • 恒溫環型核酸擴增
      • 轉錄媒介增幅
    • 聚合酵素鏈鎖反應
      • 嵌套聚合酵素鏈鎖反應
      • 即時聚合酵素鏈鎖反應

9. CT/NG檢測市場依產品類型分類

  • 耗材和試劑
    • 控制材料
    • 套件
    • 探針和引子
  • 裝置
    • 自動化系統
    • 雜合反應分析設備
    • 聚合酵素鏈鎖反應裝置
  • 軟體和服務

第 10 章：最終用戶 CT/NG 檢測市場

  • 學術研究機構
  • 診所
  • 診斷實驗室
  • 醫院

第 11 章：按測試類型分類的 CT/NG 測試市場

  • 披衣菌感染檢測
  • 雙重檢查
  • 淋病檢測

第12章：按地區分類的 CT/NG 檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章：CT/NG 檢測市場（按群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：按國家分類的CT/NG檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Hologic, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Danaher Corporation
    • bioMerieux SA
    • QIAGEN NV
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • PerkinElmer, Inc.
Product Code: MRR-777F3B3232BF

The CT/NG Testing Market is projected to grow by USD 3.16 billion at a CAGR of 7.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.74 billion
Estimated Year [2025] USD 1.87 billion
Forecast Year [2032] USD 3.16 billion
CAGR (%) 7.70%

A clear and strategic orientation to diagnostic evolution for chlamydia and gonorrhea testing that frames technology, clinical utility, and procurement implications for executives

This executive summary introduces a comprehensive analytical review of current clinical diagnostic dynamics for Chlamydia and Gonorrhea testing, emphasizing technological trajectories, stakeholder behavior, and operational pressures that are reshaping clinical practice. The narrative situates diagnostic innovation within the broader context of healthcare delivery, where diagnostic accuracy, turnaround time and integration with care pathways increasingly determine clinical utility and procurement decisions. As such, this document seeks to orient senior leaders to the critical inflection points influencing diagnostic adoption while clarifying practical considerations for clinical operations and commercial strategy.

Importantly, the introduction frames the diagnostic landscape through multiple lenses: technological capability across culturing methods, hybridization assays, immunoassays and nucleic acid amplification tests; product and service composition including consumables, instruments and software; as well as end-user requirements spanning academic and research institutes, clinics, diagnostic laboratories and hospitals. By establishing this structured perspective, subsequent sections translate technical detail into strategic implications for clinical practice, supply chains and regulatory engagement. As a result, readers should expect clear linkages between diagnostic modalities and real-world deployment scenarios, enabling informed prioritization of investments and partnership opportunities.

How molecular acceleration, multiplex testing, and decentralized diagnostics are collectively reshaping clinical workflows and procurement strategies in CT/NG testing

Transformative shifts in the diagnostic landscape are driven by accelerating molecular adoption, rising demand for multiplexing, and a stronger emphasis on decentralized testing models that bring high-sensitivity assays closer to point-of-care settings. Nucleic acid amplification tests have moved from centralized labs into rapid workflows, supported by advances in isothermal methods and increasingly robust polymerase chain reaction platforms. Consequently, clinical pathways are adapting to favor tests that reduce time-to-result while preserving diagnostic fidelity, prompting health systems and clinics to reassess laboratory routing and triage protocols.

Meanwhile, integration of software and data management tools is changing how test results are interpreted and acted upon, with automated analyzers and connected instruments enhancing throughput and reducing manual errors. This technological shift interacts with evolving regulatory expectations and quality frameworks, requiring manufacturers and laboratory managers to invest in validation, traceability and interoperability. In parallel, the convergence of consumables innovation, assay design and instrument capability is unlocking more practical dual testing strategies, enabling simultaneous detection of Chlamydia trachomatis and Neisseria gonorrhoeae in a single workflow. Together, these dynamics are driving strategic reassessments across clinical, commercial and operational functions, and they demand coordinated responses across R&D, manufacturing and customer support teams.

Assessment of the 2025 United States tariff effects on diagnostic supply chains, procurement practices, and manufacturer localization decisions with operational implications

Cumulative impacts of tariff changes implemented in the United States in 2025 have material consequences for the diagnostic supply chain, procurement decision-making and manufacturer cost structures. Tariff adjustments on imported reagents, instruments and certain components have elevated landed costs, prompting purchasers and suppliers alike to reassess sourcing strategies and to explore alternative logistics models. In response, many stakeholders have accelerated nearshoring discussions, diversified supplier portfolios and re-evaluated inventory buffers to preserve continuity of testing services and to manage episodic price volatility.

These trade policy shifts also influence product roadmaps and investment timelines. Manufacturers that previously relied on low-cost international supply chains are now compelled to examine localized manufacturing or to negotiate revised commercial terms with distributors. As a result, procurement teams are prioritizing greater contractual transparency and longer-term supply agreements to stabilize access to critical consumables and PCR instruments. From a clinical perspective, the tariffs underscore the importance of resilient supply planning: diagnostic laboratories and hospital networks are increasingly focused on identifying validated alternative assays and redundant instrument platforms to mitigate the operational risks associated with constrained reagent availability and fluctuating import costs.

Integrated segmentation analysis reveals how technology variants, product composition, end-user requirements, and test types converge to drive diagnostic selection and implementation strategies

Key segmentation insights illuminate how technology choices, product formats, end-user needs and test types intersect to shape adoption pathways and procurement priorities. Technology segmentation ranges across culturing methods, hybridization assays, immunoassays and nucleic acid amplification tests; within nucleic acid amplification, stakeholders differentiate between isothermal amplification and polymerase chain reaction, while isothermal approaches encompass loop mediated isothermal amplification and transcription mediated amplification and polymerase chain reaction may involve nested PCR and real time PCR variants, each offering distinct performance, throughput and workflow trade-offs. These technological distinctions drive clinical suitability criteria and laboratory integration requirements and should inform evaluation protocols when selecting diagnostic solutions.

Product type segmentation separates consumables and reagents, instruments, and software and services; consumables and reagents include control materials, kits, and probes and primers, while instruments range from automated systems to hybridization analyzers and PCR instruments, and software and services address data management, connectivity and lifecycle support. End-user segmentation identifies academic and research institutes, clinics, diagnostic laboratories and hospitals, each of which has unique throughput demands, accreditation constraints and purchasing cadences that influence product selection. Test type segmentation highlights chlamydia tests, dual tests and gonorrhea tests, with dual tests gaining traction for their operational efficiency and clinical value in settings seeking consolidated diagnostic pathways. Taken together, these segmentation lenses provide a structured way to prioritize investment, validation and commercialization efforts according to target users and use cases.

Regional differentiation in diagnostic adoption, regulatory complexity, and procurement behavior across Americas, Europe, Middle East & Africa, and Asia-Pacific requiring tailored commercial approaches

Regional dynamics vary in regulatory context, clinical adoption, and supply chain architecture across the Americas, Europe, Middle East & Africa, and Asia-Pacific, producing differentiated priorities for manufacturers and purchasers. In the Americas, demand for rapid, high-sensitivity molecular diagnostics and established laboratory networks supports broad adoption of nucleic acid amplification and automated systems, yet procurement teams remain attentive to cost and supply continuity concerns. Conversely, in Europe, Middle East & Africa, heterogeneous regulatory regimes and variable healthcare infrastructure create a mosaic of market entry considerations, necessitating adaptive go-to-market strategies and flexible validation packages that accommodate divergent accreditation pathways.

The Asia-Pacific region exemplifies rapid innovation adoption in certain urban centers alongside significant variability in clinical infrastructure across markets, which amplifies the value of modular instrument platforms and adaptable reagent kits. Across all regions, dual testing modalities and point-of-care options are becoming increasingly relevant as health systems prioritize streamlined patient pathways and reduced follow-up visits. Furthermore, regional procurement policies, public health screening programs and reimbursement environments continue to shape end-user purchasing behavior, underscoring the need for tailored commercial models, local partnerships and regulatory preparedness to succeed across diverse geographies.

Competitive capabilities analysis highlighting assay innovation, instrument automation, digital connectivity, and supply resilience that define success for diagnostic companies

Leading companies in the diagnostic ecosystem are advancing differentiated strategies across assay innovation, instrument automation, and digital connectivity, while simultaneously navigating regulatory scrutiny and supply chain constraints. Successful players are those that pair robust R&D pipelines-focused on high-sensitivity nucleic acid amplification and multiplex assay development-with scalable manufacturing capabilities for consumables and reagents. In parallel, investment in automated platforms, hybridization analyzers and PCR instruments that simplify workflow adoption and reduce hands-on time remains a principal differentiator for customers seeking operational efficiency.

Strategic partnerships and OEM arrangements are increasingly common as firms seek to accelerate time-to-market and broaden distribution reach. Companies that augment product offerings with software and services that enable result management, analytics and compliance support tend to achieve deeper integration within health systems. Additionally, those that maintain flexible supply models and transparent quality systems are better positioned to reassure large institutional customers and to respond to procurement tenders. Taken together, these capabilities-innovation, scale, connectivity and supply resilience-constitute the core attributes that define competitive advantage in the current CT/NG diagnostic landscape.

Actionable strategy recommendations for leaders to align R&D, manufacturing flexibility, interoperability, and tailored commercial models to accelerate adoption and reduce exposure to disruption

Industry leaders should prioritize an integrated strategy that aligns technological investments, supply chain resilience, and customer-centric support to capture clinical and commercial opportunities. First, directing R&D toward robust nucleic acid amplification assays and multiplex or dual test formats will meet clinical demand for rapid, accurate and consolidated diagnostics while improving clinical workflow efficiency. Second, strengthening manufacturing flexibility-either through nearshoring, contract manufacturing partnerships, or diversified supplier networks-will mitigate risks tied to trade policy changes and reduce exposure to single-source disruptions.

In addition, companies should enhance instrument and software interoperability to lower barriers to adoption among laboratories and clinics that operate heterogeneous analyzer fleets. Strategic investments in regulatory intelligence and expedited validation pathways will facilitate quicker market access across diverse geographies. Furthermore, building tailored commercial models for academic and research institutes, clinics, diagnostic laboratories and hospitals-each with their own purchasing rhythms-will improve conversion and retention. Finally, pursuing collaborative initiatives with public health programs and clinical networks can reinforce credibility and accelerate uptake, especially for dual testing solutions that offer immediate operational value in screening and treatment workflows.

A rigorous multi-method research framework combining primary stakeholder interviews, technical assay evaluation, and secondary evidence to produce validated, actionable diagnostic insights

The research approach employed a multi-method framework combining primary stakeholder engagement, technical assay review and secondary literature synthesis to deliver robust, actionable insights. Primary research included structured interviews with laboratorians, clinical decision-makers, procurement leaders and regulatory specialists to capture operational constraints, validation expectations and adoption drivers. These engagements were complemented by technical reviews of assay design, instrument specifications and workflow integration to compare performance characteristics and suitability across different use cases.

Secondary research drew on public regulatory documentation, clinical guidelines and peer-reviewed literature to contextualize clinical utility and evidence standards for nucleic acid amplification, hybridization assays and immunoassays. Data synthesis relied on triangulation across sources to validate thematic findings and to surface consistent operational patterns. Quality assurance measures included cross-validation of interview insights, methodical documentation of data provenance, and internal peer review to ensure analytical rigor. This layered methodology ensures that conclusions and recommendations are grounded in real-world practice while remaining sensitive to regulatory and supply chain realities.

Synthesis of diagnostic trends showing how technology convergence, operational resilience, and targeted commercialization must align to sustain adoption and clinical impact

In conclusion, the CT/NG diagnostic landscape is in active transition as molecular techniques, instrument automation and data integration converge to improve clinical pathways and operational efficiency. The rise of dual testing approaches and the increasing feasibility of decentralized testing are reshaping where and how testing occurs, while tariff-driven supply chain pressures emphasize the need for manufacturing flexibility and procurement transparency. Taken together, these themes point to a future in which technological capability must be matched by resilient operations and targeted commercial engagement to achieve sustainable adoption.

For decision-makers, the imperative is clear: align product development and commercialization plans with the practical constraints of end-users, regional regulatory environments and supply chain realities. By doing so, organizations can accelerate clinical impact, strengthen customer relationships and reduce operational risk. The path forward requires coordinated investment across assay innovation, instrument interoperability and supply network design, alongside proactive regulatory planning and tailored go-to-market strategies that reflect the nuanced needs of academic institutions, clinical laboratories, clinics and hospitals.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of point-of-care molecular diagnostics reducing turnaround times in CT/NG testing
  • 5.2. Integration of digital health platforms to streamline CT/NG test ordering and patient follow up
  • 5.3. Adoption of multiplex syndromic panels combining CT/NG detection with other STI targets to improve diagnostics
  • 5.4. Rising demand for at-home self-collection kits for CT/NG screening driven by telemedicine expansion
  • 5.5. Impact of antimicrobial resistance surveillance on gonorrhea NAAT assay development and market dynamics
  • 5.6. Regulatory shift towards FDA clearance of next generation screening assays for CT/NG detection
  • 5.7. Emerging use of CRISPR based diagnostics to enhance sensitivity in chlamydia and gonorrhea testing workflows

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CT/NG Testing Market, by Technology

  • 8.1. Culturing Methods
  • 8.2. Hybridization Assays
  • 8.3. Immunoassays
  • 8.4. Nucleic Acid Amplification Tests
    • 8.4.1. Isothermal Amplification
      • 8.4.1.1. Loop Mediated Isothermal Amplification
      • 8.4.1.2. Transcription Mediated Amplification
    • 8.4.2. Polymerase Chain Reaction
      • 8.4.2.1. Nested Polymerase Chain Reaction
      • 8.4.2.2. Real Time Polymerase Chain Reaction

9. CT/NG Testing Market, by Product Type

  • 9.1. Consumables And Reagents
    • 9.1.1. Control Materials
    • 9.1.2. Kits
    • 9.1.3. Probes And Primers
  • 9.2. Instruments
    • 9.2.1. Automated Systems
    • 9.2.2. Hybridization Analyzers
    • 9.2.3. Polymerase Chain Reaction Instruments
  • 9.3. Software And Services

10. CT/NG Testing Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Clinics
  • 10.3. Diagnostic Laboratories
  • 10.4. Hospitals

11. CT/NG Testing Market, by Test Type

  • 11.1. Chlamydia Tests
  • 11.2. Dual Tests
  • 11.3. Gonorrhea Tests

12. CT/NG Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. CT/NG Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. CT/NG Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Hologic, Inc.
    • 15.3.2. F. Hoffmann-La Roche Ltd.
    • 15.3.3. Abbott Laboratories
    • 15.3.4. Becton, Dickinson and Company
    • 15.3.5. Danaher Corporation
    • 15.3.6. bioMerieux SA
    • 15.3.7. QIAGEN N.V.
    • 15.3.8. Siemens Healthineers AG
    • 15.3.9. Thermo Fisher Scientific Inc.
    • 15.3.10. PerkinElmer, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CT/NG TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CT/NG TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CT/NG TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CT/NG TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CT/NG TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CT/NG TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CT/NG TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CT/NG TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CT/NG TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CT/NG TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CT/NG TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CT/NG TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CT/NG TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CT/NG TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CT/NG TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY ISOT